Author Archives: Jan De Backer

Immunotherapy, lung tumors and blood vessels: what’s really happening?

In this case study we used the quantitative CT approach called Functional Respiratory Imaging (FRI) to assess the effect of immunotherapy on nodule volume and blood vessel volume.

The female patient in this study was diagnosed with Non-Small Cell Lung Cancer (NSCLC) in the right upper lobe (RUL) and presented with no other respiratory disease. 

The patient was treated with a new type of immunotherapy to reduce the size of tumors. An HRCT scan at total lung capacity (TLC) was taken at baseline and after 4 months of treatment with immunotherapy. The baseline analysis clearly showed the nodule in the right upper lobe with a volume of 21.04 ml.

The blood vessel volume in the right upper lobe was 117% predicted so 17% above the normal value likely caused by the additional vascularization of the tumor. The blood vessel volumes in the other lobes ranged from 103% predicted in the right lower lobe (RLL) to 116% predicted in the left upper lobe (LUL) with the average blood vessel volume at 110% predicted. 

After three months of therapy, the second analysis was performed to detect changes in the volume of the nodule and the blood vessel volumes. The volume of the nodule was approximately 50% reduced compared to baseline which demonstrates the effect of this new drug administration for this patient.

Interestingly also the blood vessel volumes were significantly reduced over all lobes with an average 90% predicted (reduction of around 20% predicted!) with a low of 73% in the right middle lobe (RML).

This finding begs the question what are the side effects of effective immunotherapies and how does this affect the patient in the short and long term? Novel imaging approaches such as FRI especially in combination with machine learning can provide valuable insights using a holistic approach leading to early and effective treatments. This is especially true when associated with a ramp up of CT based screening programs for lung cancer.

FLUIDDA at ERS2018 in Paris

For the next 5 days the FLUIDDA team will be present at the annual European Respiratory Society conference in Paris. We are looking forward to welcome you at booth 6 in block F. Here you can find out all the latest developments on how our Functional Respiratory Imaging solutions can assist in the development of… Continue Reading

FRI shows clinically meaningful benefits of Bevespi in COPD

We are happy to announce that a few days ago the positive results of AstraZeneca’s Bevespi (LABA/LAMA), compared to placebo have been published in the International Journal of COPD. The study shows how FRI confirmed the strong, homogeneous effect of the innovative co-suspension bronchodilator compared to placebo, as seen in earlier studies. At the same… Continue Reading

FRI and disease characterization: Idiopathic pulmonary fibrosis

A thorough understanding of a pharmaceutical company’s target disease is imperative when it wants to successfully develop and market its respiratory drug. Often, conventional lung function parameters lack the sensitivity and level of detail to fully capture a disease and this leads to very expensive developments in the respiratory field. This is especially the case in… Continue Reading

How is FRI a solution to your research question?

How is FRI a solution to your research question?

  We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of several clinical biomarkers make it difficult for therapy developers to limit the size of their trails. Similarly, in the clinical domain, high costs occur among others from insensitive or difficult measurements, late detection of… Continue Reading

I:E and breathing control in CF drug delivery – what makes or breaks treatment?

  Cystic fibrosis (CF) is a devastating, chronic disease that affects over 100,000 people worldwide. The consequences patients need to bear with them for the rest of their lives are even more devastating. A CF patient is signed for continuous care, daily treatments, hours of daily physiotherapy sessions and regular hospital check-ups or visits, next… Continue Reading

FDA to support FLUIDDA’s FRI technology in the quest for more affordable drugs

The US Food and Drug administration has issued a letter of support to FLUIDDA after examination of study results where Functional Respiratory Imaging was used to assess bio-equivalence between a generic and a reference drug. Manufacturers of generic drugs are required to demonstrate that their drugs are therapeutically equivalent to the reference drug before they… Continue Reading

UCSF and FLUIDDA enter into a new research collaboration

Los Angeles, January 5th 2018 FLUIDDA Inc and the University of California, San Francisco (UCSF) are entering into a new research collaboration as of December 2017. Together with the team of Dr. John Fahy (Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Medicine and investigator in the Cardiovascular Research… Continue Reading